Loading clinical trials...
Loading clinical trials...
Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease (TRAIL1)
Conditions
Interventions
Pirfenidone
Placebo
Locations
33
United States
University of Alabama Site at Birmingham
Birmingham, Alabama, United States
University of California San Francisco
San Francisco, California, United States
National Jewish Health
Denver, Colorado, United States
University of Miami
Miami, Florida, United States
Tulane Medical Center
New Orleans, Louisiana, United States
John Hopkins Medicine
Baltimore, Maryland, United States
Start Date
April 7, 2017
Primary Completion Date
April 7, 2021
Completion Date
April 7, 2021
Last Updated
August 16, 2022
Lead Sponsor
Brigham and Women's Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions